Walking Speed and Health‐Related Quality of Life in Multiple Sclerosis

Kohn, Christine G.; Baker, William L.; Sidovar, Matthew; Coleman, Craig I.

doi:10.1007/s40271-013-0028-x

Cited by 36 publications

(30 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Walking speed has been reported as an important predictor of functional performance and patient-reported HRQOL [27,28]. Patients from the present study showed a significant increase in gait speed and cadence between the 6-and 12-month follow-up.…”

Section: Discussionsupporting

confidence: 51%

“…The difference between the present study and studies reporting on associations between gait speed and HRQOL may be due to a difference in the level of comorbidity between the patient groups. In general, patients with tibial shaft fractures are young and have a low level of comorbidity, compared to patients with multiple sclerosis and elderly people with osteoporosis, in which a strong association between gait speed and QOL is commonly reported [27,28].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Asymmetry in gait pattern following tibial shaft fractures – a prospective one-year follow-up study of 49 patients

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 51%

Section: Discussionmentioning

confidence: 99%

Asymmetry in gait pattern following tibial shaft fractures – a prospective one-year follow-up study of 49 patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Ambulation and mobility limitations were reported by MS patients as affecting their QOL (which was not assessed with standardized questionnaires) in a large population-based survey (La Rocca, 2011). In another survey of over 3,000 individuals with MS in the North American Research Committee on Multiple Sclerosis (NARCOMS) registry, those who reported an impact of MS on walking speed also reported poorer quality of life on a variety of measures, including the EQ-5D (Kohn et al, 2014). These associations remained significant but were weaker after adjustment for demographic, disease-related, and symptom-related variables.…”

Section: Discussionmentioning

confidence: 99%

Correlates of the timed 25 foot walk in a multiple sclerosis outpatient rehabilitation clinic

Béthoux

Palfy

Plow

2016

International Journal of Rehabilitation Research

View full text Add to dashboard Cite

The Timed 25 Foot Walk (T25FW), a test of maximum walking speed on a short distance, is commonly used to monitor ambulation status and to assess treatment outcomes in MS. The main goal of this study was to determine how walking speed on the T25FW correlates with other clinician-reported and patient-reported measures in an outpatient MS rehabilitation clinic. We analyzed cross-sectional data systematically collected during a physiatry evaluation for the management of spasticity and walking limitations. In addition to demographic variables and the Expanded Disability Status Scale (EDSS), measures of body functions [lower extremity manual muscle testing (LE MMT), lower extremity Modified Ashworth Scale (LE MAS), Fatigue Severity Scale (FSS), leg pain], and measures of activity and quality of life [reported frequency of falls, Incapacity Status Scale (ISS), Rivermead Mobility Index (RMI), EQ-5D health questionnaire, and Patient Health Questionnaire-9 items (PHQ-9)] were administered. A multivariate regression analysis was conducted. 199 patients were included in the analysis (age 49.41(9.89) years, disease duration 15.40 (10.22) years, EDSS score 5.6 (1.2), and T25FW speed 70.93(44.13) cm/s). Both EDSS and LE MMT were significantly correlated with T25FW speed (R square 0.692, p<0.001). After adjusting for EDSS and LE MMT, lower T25FW speed was associated with higher ISS scores (R square=0.316, p<0.001), lower RMI scores (R square=0.540, p<0.001), and higher frequency of falls. EQ-5D and PHQ-9 were not significantly associated with T25FW speed. Our findings support the clinical relevance of the T25FW in the rehabilitation of patients with MS.

show abstract

“…MS is a debilitating disease that can result in walking impairment [1,19]. Previous studies have demonstrated an association between walking speed and quality of life, suggesting that greater walking disability leads to reduced quality of life [2]. In the pivotal phase 3 clinical studies, PR-fampridine was shown to improve walking ability [6,7], while post-marketing and placebo-controlled studies also demonstrated improvements in dynamic and static balance [12,20].…”

Section: Discussionmentioning

confidence: 99%

“…Walking impairment is a common disability among persons with multiple sclerosis (MS) and has a negative impact on quality of life [1,2]. Walking disability can reduce independence, with lower limb function identified as the most important bodily function in a study of persons with MS [3].…”

Section: Introductionmentioning

confidence: 99%

Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29

Gasperini

Hupperts

Lycke

et al. 2016

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Prolonged-release (PR) fampridine is approved to treat walking impairment in persons with multiple sclerosis (MS); however, treatment benefits may extend beyond walking. MOBILE was a phase 2, 24-week, double-blind, placebo-controlled exploratory study to assess the impact of 10mg PR-fampridine twice daily versus placebo on several subject-assessed measures. This analysis evaluated the physical and psychological health outcomes of subjects with progressing or relapsing MS from individual items of the Multiple Sclerosis Impact Scale (MSIS-29). PR-fampridine treatment (n=68) resulted in greater improvements from baseline in the MSIS-29 physical (PHYS) and psychological (PSYCH) impact subscales, with differences of 89% and 148% in mean score reduction from baseline (n=64) at week 24 versus placebo, respectively. MSIS-29 item analysis showed that a higher percentage of PR-fampridine subjects had mean improvements in 16/20 PHYS and 6/9 PSYCH items versus placebo after 24weeks. Post hoc analysis of the 12-item Multiple Sclerosis Walking Scale (MSWS-12) improver population (≥8-point mean improvement) demonstrated differences in mean reductions from baseline of 97% and 111% in PR-fampridine MSIS-29 PHYS and PSYCH subscales versus the overall placebo group over 24weeks. A higher percentage of MSWS-12 improvers treated with PR-fampridine showed mean improvements in 20/20 PHYS and 8/9 PSYCH items versus placebo at 24weeks. In conclusion, PR-fampridine resulted in physical and psychological benefits versus placebo, sustained over 24weeks.

show abstract

Walking Speed and Health‐Related Quality of Life in Multiple Sclerosis

Abstract: Incremental decrements in HRQoL were observed as patients perceived greater levels of reduction in their walking speed.

Cited by 36 publications

References 12 publications

Asymmetry in gait pattern following tibial shaft fractures – a prospective one-year follow-up study of 49 patients

Asymmetry in gait pattern following tibial shaft fractures – a prospective one-year follow-up study of 49 patients

Correlates of the timed 25 foot walk in a multiple sclerosis outpatient rehabilitation clinic

Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29

Contact Info

Product

Resources

About